Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,946 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Covid19 Pneumonia Clear all
Completed Phase 2 Interventional Results available

Crizanlizumab for Treating COVID-19 Vasculopathy

NCT04435184
View directory record Official record
Conditions
COVID-19
Interventions
Crizanlizumab, 0.9% saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 4, 2026, 4:15 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition

NCT04573634
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Not listed
Lead sponsor
Jill M Kolesar
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available

Examining How a Facilitated Self-Sampling Intervention and Testing Navigation Intervention Influences COVID-19 Testing

NCT05606016
View directory record Official record
Conditions
COVID-19
Interventions
Facilitated Self-Sampling Intervention (FSSI), Testing Navigation Intervention (TNI)., Control
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
1,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Brownsville, Texas • Houston, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Terminated Not applicable Interventional

Data-driven Approaches to Healthcare Provider Resilience & Burnout During COVID-19

NCT04922632
View directory record Official record
Conditions
Burnout, Professional, Exhaustion, Caregiver, Covid19
Interventions
Transcendental Meditation (TM), Experience Resolution Methodology (ERM), Transcendental Meditation (TM) and Experience Resolution Methodology (ERM), Treatment As Usual (TAU)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)

NCT05894564
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
103
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use

NCT04595084
View directory record Official record
Conditions
Depression, Anxiety, Substance Use, Stress, Psychological, Stress, Emotional, Alcohol Use, Unspecified, Drug Use, Covid19
Interventions
Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell, Internet Cognitive Behavioral Therapy plus CHAMindWell, CHAMindWell
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 70 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

NCT04734860
View directory record Official record
Conditions
Covid19
Interventions
COVI-AMG, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Bradenton, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 4, 2026, 4:15 AM EDT
Not listed Not applicable Interventional

Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients

NCT04581161
View directory record Official record
Conditions
Acute Respiratory Failure, Covid19
Interventions
Life2000® Ventilator
Device
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Directed Topical Drug Delivery for Treatment for PASC Hyposmia

NCT05970731
View directory record Official record
Conditions
Post Acute Sequelae Covid-19 Hyposmia
Interventions
Beclomethasone, Placebo, Microsponge
Drug · Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

NCT05594602
View directory record Official record
Conditions
COVID-19
Interventions
EDP-235, Itraconazole, Carbamazepine, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 4, 2026, 4:15 AM EDT
Withdrawn Phase 2 Interventional

Anakinra, COVID-19, Cytokine Storm

NCT04603742
View directory record Official record
Conditions
Covid19, Cytokine Storm, Mechanical Ventilation Complication
Interventions
Anakinra, 0.9% Saline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

NCT04895982
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID19
Interventions
BNT162b2
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
15
States / cities
Jefferson, Louisiana • Kenner, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 4, 2026, 4:15 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

NCT04323761
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Remdesivir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 130 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 4, 2026, 4:15 AM EDT
No Longer Available No phase listed Expanded access

SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19

NCT04355494
View directory record Official record
Conditions
COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
Interventions
eculizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Newton, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 4, 2026, 4:15 AM EDT
Completed No phase listed Observational

COVID-19 Mortality Prediction Model

NCT04358510
View directory record Official record
Conditions
COVID-19, Pneumonia, Mechanical Ventilation
Interventions
COViage
Device
Lead sponsor
Dascena
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

NCT04519437
View directory record Official record
Conditions
Healthy, Chronic Stable Illness
Interventions
REGN10933+REGN10987, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Long COVID-19 [11C]CPPC Study

NCT06223971
View directory record Official record
Conditions
COVID Long-Haul
Interventions
[11C]CPPC Injection
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of LAM-002A for the Prevention of Progression of COVID-19

NCT04446377
View directory record Official record
Conditions
COVID-19 Disease
Interventions
Apilimod Dimesylate Capsule, Placebo
Drug · Other
Lead sponsor
OrphAI Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 4, 2026, 4:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2

NCT06848309
View directory record Official record
Conditions
Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
Interventions
Bronchoscopy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Terminated Not applicable Interventional

Long COVID-19 Rehabilitation & Recovery Research Program

NCT05398692
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, COVID-19
Interventions
On Site Exercise Rehabilitation
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 4, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 4, 2026, 4:15 AM EDT
Withdrawn Phase 2 Interventional

Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19

NCT04344236
View directory record Official record
Conditions
COVID-19
Interventions
Saline oral/nasal rinse, 0.5% Povidone/Iodine oral/nasal rinse, 0.12% Chlorhexidine oral/nasal rinse
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 4, 2026, 4:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects

NCT04667442
View directory record Official record
Conditions
Covid19
Interventions
Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)
Diagnostic Test
Lead sponsor
Nanomix
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Emeryville, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 4, 2026, 4:15 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

NCT07149428
View directory record Official record
Conditions
Respiratory Tract Infection, Smell Disorder, Influenza, Rhinosinusitis, COVID-19, Depression, Parosmia, Hyposomia, Normosomia, Anosmia
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 4, 2026, 4:15 AM EDT